Windtree Therapeutics, Inc. (WINT)

NASDAQ: WINT · IEX Real-Time Price · USD
0.318
+0.005 (1.60%)
At close: Feb 23, 2024, 4:00 PM
0.307
-0.011 (-3.37%)
After-hours: Feb 23, 2024, 6:13 PM EST
1.60%
Market Cap 2.07M
Revenue (ttm) n/a
Net Income (ttm) -24.83M
Shares Out 6.51M
EPS (ttm) -19.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 70,105
Open 0.320
Previous Close 0.313
Day's Range 0.301 - 0.320
52-Week Range 0.280 - 18.480
Beta 0.62
Analysts Hold
Price Target 1.00 (+214.86%)
Earnings Date Apr 1, 2024

About WINT

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 8, 1995
Employees 20
Stock Exchange NASDAQ
Ticker Symbol WINT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for WINT stock is "Hold" and the 12-month stock price forecast is $1.0.

Price Target
$1.0
(214.86% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

24 days ago - GlobeNewsWire

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

WARRINGTON, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

25 days ago - GlobeNewsWire

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

WARRINGTON, PA / ACCESSWIRE / January 26, 2024 / Windtree Therapeutics (NASDAQ:WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15 mil...

4 weeks ago - Accesswire

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

4 weeks ago - GlobeNewsWire

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

WARRINGTON, PA / ACCESSWIRE / January 18, 2024 / Greater China holds a significant, if not the world's largest, acute heart failure patient population. It may be a market where drug treatment innovati...

5 weeks ago - Accesswire

Windtree Therapeutics Announces License Agreement with Lee's Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for prod...

5 weeks ago - GlobeNewsWire

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

The new preclinical data further supports istaroxime clinical data  from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute...

7 weeks ago - GlobeNewsWire

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024

WARRINGTON, PA / ACCESSWIRE / December 19, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT) has recently enrolled the first subject in its phase 2 SEISMiC Extension Study to evaluate istaroxime in the...

2 months ago - Accesswire

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

SEISMiC Extension Study results are anticipated in mid-2024  and expected to provide dose optimization for Phase 3

2 months ago - GlobeNewsWire

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company's current lead program This class of SERCA2a Activators selectively ...

3 months ago - GlobeNewsWire

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

3 months ago - GlobeNewsWire

Windtree to Present at the Sidoti Micro Cap Conference on November 16th

WARRINGTON, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

3 months ago - GlobeNewsWire

Windtree to Present at the ThinkEquity Conference on October 19th in New York City

WARRINGTON, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

4 months ago - GlobeNewsWire

Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th

WARRINGTON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

4 months ago - GlobeNewsWire

Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th

WARRINGTON, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

5 months ago - GlobeNewsWire

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients Patent provides protection through late 2039 for drug candidates w...

6 months ago - GlobeNewsWire

Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

WARRINGTON, PA / ACCESSWIRE / August 16, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biotechnology company developing treatments for severe cardiovascular disorders. It is targeting patients...

6 months ago - Accesswire

Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates

Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3; Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway

7 months ago - GlobeNewsWire

Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure

WARRINGTON, PA / ACCESSWIRE / July 25, 2023 / Windtree Therapeutics Inc. (NASDAQ:WINT) is looking to revolutionize acute care treatment for patients with serious conditions like acute heart failure (A...

7 months ago - Accesswire

The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market

WARRINGTON, PA / ACCESSWIRE / July 18, 2023 / The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 t...

7 months ago - Accesswire

Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That

WARRINGTON, PA / ACCESSWIRE / July 14, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class dru...

8 months ago - Accesswire

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...

8 months ago - GlobeNewsWire

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism

This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure This family of drug candidates of SERCA2a Activat...

9 months ago - GlobeNewsWire

Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones

Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnolog...

9 months ago - GlobeNewsWire

Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for ...

10 months ago - GlobeNewsWire